Technical analysis of IN8bio, Inc. (INAB): price and volume charts, candlestick patterns, moving averages (SMA, EMA), RSI, MACD, ADX and Bollinger Bands. Identify momentum, trend direction and potential entry/exit zones.
IN8bio, Inc. is a biotechnology firm currently in the clinical trial phase, dedicated to identifying, advancing, and bringing to market gamma-delta T cell-based treatments specifically for various forms of cancer. The company's primary therapeutic asset, INB-200, is an autologous (patient-derived) gamma-delta T cell product that has been genetically engineered and is presently undergoing a Phase I clinical study for glioblastoma and other solid tumor malignancies.
Price Performance
| 1 month | -11.40% |
| 3 months | -29.37% |
| Year-to-date | -56.84% |
| 1 year | -49.50% |
| 3 years | -96.48% |
| 5 years | -99.52% |
52-Week Range
| 52-week High | $2.73 |
| 52-week Low | $0.88 |
| Avg Volume (90d) | 58K |
Technical Indicators
| SMA 50 | $1.15 |
| SMA 200 | $1.58 |
| Beta | 0.04 |
| 30-day Volatility (annualised) | 89.3% |
| Price vs SMA 50 | -12.2% |
| Price vs SMA 200 | -36.0% |
Monthly Close (12 months)
| Month | Close | Change |
|---|---|---|
| 2025-10 | $1.95 | |
| 2025-11 | $1.98 | +1.5% |
| 2025-12 | $2.34 | +18.2% |
| 2026-01 | $1.97 | -15.8% |
| 2026-02 | $1.70 | -13.7% |
| 2026-03 | $1.48 | -12.9% |
| 2026-04 | $1.47 | -0.7% |
| 2026-05 | $1.87 | +27.2% |
| 2026-06 | $1.41 | -24.6% |
| 2026-07 | $1.03 | -27.0% |
| 2026-08 | $1.10 | +6.8% |
| 2026-09 | $1.01 | -8.2% |
Upcoming Earnings
| Date | EPS Est. | Revenue Est. |
|---|---|---|
| 2026-09-14 | $-2.53 | |
| 2026-09-14 | $159M | |
| 2026-09-14 | $-0.26 | $14M |
| 2026-09-14 | ||
| 2026-09-14 | $0.84 | $26M |
| 2026-09-14 |
Price
| Price | $1.01 |
| Market Cap | $10M |
| Exchange | NASDAQ |
| Country | US |
Related companies: ACXP · APRE · APVO · BCDA · GLTO · HCWB · KPRX
Explore sector: Healthcare · Biotechnology
More sections of INAB: Overview · Financials · Valuation · Statistics · Estimates · Ownership · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks